ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06272994 (Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin), which is not on this map. Cited by 91 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc)
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 194 citations in OpenAlex.
- Pooled it
- Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2024Pooled it
- Aetiological agents of adult community-acquired pneumonia in Japan: systematic review and meta-analysis of published data.BMJ open respiratory research · 2023Pooled it
- Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Rapid and actionable nasal-swab screening supports antimicrobial stewardship in patients with pneumonia: a prospective study.Antimicrobial resistance and infection control · 2025Trial
- Trial
- Evaluation of the Impact of Universal Mupirocin Decolonization in Intensive Care Units on the Utility of Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Testing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Genomic Characterization and Virulence Determinants ofAntibiotics (Basel, Switzerland) · 2026Article
- Impact of Methicillin-ResistantOpen forum infectious diseases · 2026Article
- Resistance to Lefamulin: An Evaluation of Data from In Vitro Antimicrobial Susceptibility Studies.Antibiotics (Basel, Switzerland) · 2026Review
- Case Report: Rare Community-Acquired Pneumonia with Concurrent Methicillin-ResistantInfection and drug resistance · 2026Article
- Clinical Application of Blood Lactate, C-Reactive Protein, and the Age-Adjusted Charlson Comorbidity Index in Predictive Assessment of Malignant Risk of MRSA Pneumonia.Mediators of inflammation · 2026Article
- Investigating risk factors for methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in community acquired pneumonia: a model for using only electronic data capture.Pneumonia (Nathan Qld.) · 2025Article
- M28 family peptidase derived fromGut microbes · 2025Article
- Rapid Detection ofBiosensors · 2025Article
- Characterisation of nasopharyngeal colonisation byBMJ open respiratory research · 2025Article
- Burden of non-COVID-19 lower respiratory infections and etiologies in China and globally: An analysis for the global burden of disease study 2021.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Targeting Bacterial Adenylate Kinase mRNA with a Chimeric Antisense Oligonucleotide for Rational Antibacterial Drug Development.Molecules (Basel, Switzerland) · 2025Article
- Prevotella intermedia Synergistically Exacerbates Pneumonia Induced by Oral Streptococci.The Journal of infectious diseases · 2025Article
- Cytokine-mediated inhibition of Staphylococcus aureus adherence and invasion into nonphagocytic cells.Medical microbiology and immunology · 2025Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundPrevalence of Staphylococcus aureus community-acquired pneumonia (CAP) and its clinical features remain incompletely understood, complicating empirical selection of antibiotics.
methodsUsing a multicenter, prospective surveillance study of adults hospitalized with CAP, we calculated the prevalence of methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) among all CAP episodes. We compared the epidemiologic, radiographic, and clinical characteristics of S. aureus CAP (per respiratory or blood culture) with those of pneumococcal (per respiratory or blood culture or urine antigen) and all-cause non-S. aureus CAP using descriptive statistics.
resultsAmong 2259 adults hospitalized for CAP, 37 (1.6%) had S. aureus identified, including 15 (0.7%) with MRSA and 22 (1.0%) with MSSA; 115 (5.1%) had Streptococcus pneumoniae Vancomycin or linezolid was administered to 674 (29.8%) patients within the first 3 days of hospitalization. Chronic hemodialysis use was more common among patients with MRSA (20.0%) than pneumococcal (2.6%) and all-cause non-S. aureus (3.7%) CAP. Otherwise, clinical features at admission were similar, including concurrent influenza infection, hemoptysis, multilobar infiltrates, and prehospital antibiotics. Patients with MRSA CAP had more severe clinical outcomes than those with pneumococcal CAP, including intensive care unit admission (86.7% vs 34.8%) and in-patient mortality (13.3% vs 4.4%).
conclusionsDespite very low prevalence of S. aureus and, specifically, MRSA, nearly one-third of adults hospitalized with CAP received anti-MRSA antibiotics. The clinical presentation of MRSA CAP overlapped substantially with pneumococcal CAP, highlighting the challenge of accurately targeting empirical anti-MRSA antibiotics with currently available clinical tools and the need for new diagnostic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.